Skip to main content

Table 5 One-way SA results

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Parameters

Base case values

One-way SA Values

Incremental costs

Incremental QALY

ICUR (€/QALY gained)

Non prophylaxis

Palivizumab

Non- prophylaxis

Palivizumab

Number of palivizumab injections per RSV season

3.88

5

€1,983.67

0.0731

27,152.79

Risk of ICU admission

17.80%

17.80%

30.00%

11.10%

€1,370.71

0.0737

18,592.52

In-hospital mortality

2.33%

2.33%

0.13%

0.09%

€1,438.90

0.0725

19,836.81

Proportion of patients that experience emergency visit prior to hospital admission

100.00%

50.00%

€1,440.49

0.0731

19,717.70

Hospital related costs* (+/−50%)

€3,031.30

+50.00% (€4.546,95)

€1,354.88

0.0731

18,545.80

−50.00% (€1515.65)

€1,523.18

0.0731

20,849.55

Direct recurrent wheezing management costs (+/−50%)

€749.57

+50.00% (€1124.36)

€1,299.30

0.0731

17,785.09

−50.00% (€.374.79)

€1,578.76

0.0731

21,610.25

Annual discount rate

Costs

Benefits

Costs

Benefits

 

3.0%

0.0%

€1,415.22

0.0799

17,704.00

5.0%

€1,453.22

0.0690

21,071.19

3.0%

1.50%

€1,439.03

0.0764

18,841.25

  1. ICU: intensive care unit; ICUR: incremental cost-utility ratio; QALY quality adjusted life years, RSV respiratory syncytial virus, SA sensitivity analysis
  2. *Hospital related costs included emergency visit prior hospitalization cost, hospital and ICU admission costs